NICE
NICE rapid review of the use of fluocinolone acetonide for chronic DMO
College Statment Since the release of TA 2711 in January 2013, NICE has undertaken a rapid review of the use of fluocinolone acetonide for chronic diabetic macular oedema2 and has recently released the FAD document for this single technology appraisal3. In the FAD document, the following guidance has been issued: Fluocinolone acetonide intravitreal implant is
NICE guidance on Ocriplasmin
College Statement Ocriplasmin is a recombinant protease enzyme that is effective in lysing fibronectin and laminin bonds at the vitreoretinal interface thus relieving vitreoretinal traction following intravitreal injection. Pivotal phase III trials have shown its effectiveness in treating vitreomacular traction leading to European Union approval in March 2013. The Royal College of Ophthalmologists welcomes the
Positive draft final guidance from NICE for Eylea® for the treatment on wet AMD
College Statement The Royal College of Ophthalmologists welcomes the NICE draft final guidance which announces that Eylea® (aflibercept) should be recommended for the treatment of patients with wet age-related macular degeneration (wAMD). Eylea® is a soluble vascular endothelial growth factor (VEGF) receptor fusion protein which binds to all forms of VEGF and placental growth factor
Intravitreal Ranibizumab injection for treatment of MO secondary to RVO
College Statement The Royal College of Ophthalmologists welcomes the decision by the National Institute for Health and Care Excellence (NICE) to recommend 0.5mg ranibizumab intravitreal injection as an option for the treatment of macular oedema secondary to central retinal vein occlusion (CRVO) and selected cases of branch retinal vein occlusion (BRVO) when laser has either
NICE rapid review of previous technology appraisal – intravitreal ranibizumab with DMO
College Statement The National Institute of Clinical Excellence (NICE) has completed a rapid review of the previous technology appraisal of the use of intravitreal ranibizumab in patients with diabetic macular oedema. The new guidance document on ranibizumab for diabetic macular oedema, (TA274), published on 27 February 2013, recommends that patients with DMO can be commenced